Cross-site comparison of gene expression data reveals high similarity. by Chu, Tzu-Ming et al.
Genomics and Risk Assessment | Mini-Monograph
Advancing the general knowledge base of
mechanisms and markers of hepatotoxicity
is of great interest to all parties involved in
this consortium. The Hepatotoxicity
Working Group of the International Life
Sciences Institute (ILSI) Health and
Environmental Sciences Institute (HESI)
Committee on the Application of Genomics
to Mechanism-Based Risk Assessment is
investigating these factors by comparing
high-density gene expression data sets gener-
ated on two sets of RNA from two indepen-
dent in vivo experiments where rats were
dosed with methapyrilene (MP) conducted
at either Abbott Laboratories (site A; Abbott
Park, IL ) or Boehringer-Ingelheim
Pharmaceuticals, Inc. (BIPI; site B;
Ridgeﬁeld, CT).
Most microarray studies are designed
with large “p” (number of genes) and small
“n” (number of arrays) characteristics. Two
issues of concern arise when investigators
work with data having such characteristics.
The first issue is of statistical inference
power where the aim is to minimize both
false-positive and false-negative rates.
Increasing sample size (i.e., n) can afford
better statistical inference power; however,
this remedy is often cost prohibitive. The
second issue arises in the attempt to address
the first concern by increasing sample size
by incorporating data sets generated at dis-
parate sites and times. Thus, the second
concern is about the consistency of such
data sets generated across multiple sites and
whether the same or similar conclusions
can be drawn. An across-site microarray
study can be useful for addressing this
issue, which is another way to increase
sample size. Conceptually, the complexities
among data generated across different sites
are higher than those of data generated
within one site. The above two issues are
related; however, the second one may be
more general and of increasing concern as
microarray data sets become increasingly
available and the desire to compare and
contrast across studies increases.
Male Sprague-Dawley rats [CRL:
CD(SD)IGS VAF/Plus] (Charles River
Laboratories, Kingston, NY) approximately
6–7 weeks of age were assigned to nine
study groups (four rats/group) and dosed by
gavage for 1, 3, or 7 days with water (vehi-
cle), 10 mg/kg/day MP, or 100 mg/kg/day
MP (Figure 1). Dose selection was based on
published and unpublished studies; the
high dose of MP was chosen to yield hepa-
totoxicity, and a nontoxic low dose was
selected. In general, the BIPI study yielded
more hepatotoxicity than the study con-
ducted at Abbott Laboratories, as defined
by clinical pathology parameters and micro-
scopic examinations of hematoxylin and
eosin–stained liver sections. No signiﬁcant
histopathological alterations were observed
in livers of rats treated with 10 mg/kg/day
MP at the 1- and 3-day time points com-
pared with alterations in livers of the con-
trol groups. In comparison, MP treatment
with 10 mg/kg/day for 7 days resulted in
minimal portal mononuclear infiltrates,
minimal hepatocellular periportal necrosis,
and minimal microvesicular hepatocellular
vacuolization. At the 100-mg/kg/day dose,
all rats showed early minimal mononuclear
portal infiltrates, minimal hepatocellular
periportal necrosis, and mild to moderate
periportal microvesicular vacuolization at 1
and 3 days of exposure. The severity of the
lesions increased at day 7, and mild hyper-
plasia became evident. In addition, in the
100-mg/kg/day MP dose group at 7 days of
exposure, moderate mononuclear portal
infiltrates were noted, and the number of
enlarged periportal hepatocytes with
microvesicular vacuolization increased. The
severity of hepatocellular periportal necrosis
at the 7-day time point also increased,
accompanied by increased numbers of
hepatocellular mitotic figures. Bile duct
hyperplasia was observed in animals in the
100-mg/kg/day dose group at 3 and 7 days.
Minimal bile duct hyperplasia was seen at
the 3-day time point and increased in sever-
ity to mild by 7 days. Levels of alanine
aminotransferase, aspartate aminotrans-
ferase, and sorbitol dehydrogenase increased
in high-dose animals in a time-dependent
manner. Total bilirubin tended to be ele-
vated in the high-dose group with contin-
ued dosing. All the above parameters were
reﬂective of liver toxicity.
An initial amount of 5–20 µg total RNA
derived from livers of rats used in those
studies was used for the synthesis of double-
stranded cDNA with a commercially
available kit (Superscript Choice System;
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Consistency and coherence of gene expression data across multiple sites depends on several factors
such as platform (oligo, cDNA, etc.), environmental conditions at each laboratory, and data qual-
ity. The Hepatotoxicity Working Group of the International Life Sciences Institute Health and
Environmental Sciences Institute consortium on the application of genomics to mechanism-based
risk assessment is investigating these factors by comparing high-density gene expression data sets
generated on two sets of RNA from methapyrilene (MP) experiments conducted at Abbott
Laboratories and Boehringer-Ingelheim Pharmaceuticals, Inc. using a single platform (Affymetrix
Rat Genome U34A GeneChip) at seven different sites. This article focuses on the evaluation of
data quality and statistical models that facilitate the comparison of such data sets at the probe
level. We present methods for exploring and quantitatively assessing differences in the data, with
the principal goal being the generation of lists of site-insensitive genes responsive to low and high
doses of MP. A combination of numerical and graphical techniques reveals important patterns
and partitions of variability in the data, including the magnitude of the site effects. Although the
site effects are signiﬁcantly large in the analysis results, they appear to be primarily additive and
therefore can be adjusted in the statistical calculations in a way that does not bias conclusions
regarding treatment differences. Key words: cross-site comparison, gene expression, hepatotoxic-
ity, ILSI, toxicogenomics. Environ Health Perspect 112:449–455 (2004). doi:10.1289/txg.6787
available via http://dx.doi.org/ [Online 15 January 2004]Invitrogen Life Technologies, Carlsbad, CA,
or Roche Molecular Biochemicals,
Mannheim, Germany) in the presence of a
T7-(dT)24 DNA oligonucleotide primer.
After synthesis, the cDNA was purified by
phenol/chloroform/isoamyl alcohol extrac-
tion and ethanol precipitation. The puriﬁed
cDNA was then transcribed in vitro (ENZO
Life Sciences, Farmingdale, NY or Ambion
Diagnostics, Austin, TX) in the presence of
biotinylated ribonucleotides to form biotin-
labeled cRNA. The labeled cRNA was then
purified on an affinity resin [RNeasy,
Qiagen (Valencia, CA)], quantified, and
fragmented. Ten to 20 µg labeled cRNA
was hybridized for approximately 16 hr at
45°C to an expression probe array. The
array was then washed and stained with
streptavidin-P-phycoerythrin (SAPE;
Molecular Probes, Inc., Eugene, OR). The
signal was amplified using a biotinylated
goat antistreptavidin antibody (Vector
Laboratories, Burlingame, CA), and the
array received a final staining with SAPE.
The GeneChip Fluidics Workstation 400
(Affymetrix, Inc., Santa Clara, CA) was used
to stain the arrays. The array was then
scanned twice using a confocal laser scanner
(GeneArray Scanner 2500, Hewlett
Packard, or Agilent, Foster City, CA), which
resulted in one scanned image.
Many factors can contribute to the
heterogeneity of data sets, including but
not limited to differences in platform
(oligo, cDNA, etc.), environmental condi-
tions at each laboratory, and data quality.
Meta-analysis performed by statistically
integrating results from different data sets
(Choi et al. 2003; Ghosh et al. 2003) is
one solution for across-site microarray
studies. When the experimental design
settings are homogenous across sites, pool-
ing data sets for a comprehensive analysis
provides direct comparisons across sites,
with better statistical inference power.
The major challenges to this end are how
to normalize data sets and how to define
and use variation across sites. 
Five well-adapted normalization
methods, including cyclic Loess (modified
from Dudoit et al. 2002), contrast-based
method (Astrand, unpublished data),
quantile normalization (Irizarry et al. 2003),
the scaling method in Affymetrix MAS 5.0
(Affymetrix, Inc. 2002), and the nonlinear
method (Li and Wong 2001; Schadt et al.
2001) are reviewed by Bolstad et al. (2003).
Quantile normalization seemed slightly bet-
ter than the others in the three types of
comparisons performed. Quantile normal-
ization makes the distribution of each chip
the same by aggressively removing specific
sources of variation (such as those associated
with chip-to-chip differences) and artiﬁcially
generating ideal distributions. Another less
aggressive way to deal with this is to normal-
ize the location and scaling of the distribu-
tion. We prefer the second approach and
have implemented that in this article. In our
opinion, quantile normalization has a poten-
tial drawback in that it can reduce the con-
sistency of the expression proﬁle of the same
probe set across arrays. This consistent
expression profile is one of the essential
characteristics of the GeneChip probe data
(Li and Wong 2001). Lowering this consis-
tency may increase the variation in down-
stream statistical modeling. An interquartile
range normalization is applied in this article
toward the same goal as quantile normaliza-
tion (i.e., to obtain consistent but not iden-
tical data distribution among chips). This
approach makes data comparable across sites
and preserves a certain level of site effects
when combining the data. The factor of site
can be easily adapted in an analysis of vari-
ance (ANOVA) model. In using variation
components naturally involved in the data,
the mixed-model approach provides ﬂexibil-
ity (Chu et al. 2002) and robustness (Chu
et al., in press) for this task. Tan and co-
workers (Tan et al. 2003) conducted a simi-
lar comparison study that demonstrated
mildly positive concordance between
Affymetrix and Amersham (Piscataway, NJ)
short oligo arrays and Agilent cDNA arrays.
Data Consistency and
Normalization
RNA samples were analyzed independently
by seven different Affymetrix platform sites
using RGU34A expression probe arrays
(Affymetrix) containing 8,799 probe sets
interrogating primarily annotated genes,
for a total of 99 chips. Each probe set con-
sisted of 16 probes; thus, each chip resulted
in 140,784 probes. The rat sequences used
for the design of the RGU34A expression
probe array were derived from the
UniGene Database build #34 (created from
Genbank 107/dbEST 11/18/98) and sup-
plemented with additional annotated gene
sequences from Genbank 110 (http://
www.ncbi.nih.gov/GenBank). UniGene
clusters are represented by a sample
sequence that is the most complete and
Mini-Monograph | Chu et al.
450 VOLUME 112 | NUMBER 4 | March 2004 • Environmental Health Perspectives
Day 1 Day 3 Day 7
Controls
Low dose
High dose
Pooled
liver RNA
Pooled
liver RNA
Pooled
liver RNA
Controls
Low dose
High dose
Pooled
liver RNA
Pooled
liver RNA
Pooled
liver RNA
Controls
Low dose
High dose
Pooled
liver RNA
Pooled
liver RNA
Pooled
liver RNA
Controls
Low dose
High dose
Pooled
liver RNA
Pooled
liver RNA
Pooled
liver RNA
Site A
Controls
Low dose
High dose
Pooled
liver RNA
Pooled
liver RNA
Pooled
liver RNA
Controls
Low dose
High dose
Pooled
liver RNA
Pooled
liver RNA
Pooled
liver RNA
Controls
Low dose
High dose
Pooled
liver RNA
Pooled
liver RNA
Pooled
liver RNA
Controls
Low dose
High dose
Pooled
liver RNA
Pooled
liver RNA
Pooled
liver RNA
Site B
Figure 1. Schematic diagram of experimental design of studies conducted at Abbott Laboratories (site A)
and Boehringer-Ingelheim Pharmaceuticals, Inc. (site B). Pooled samples were derived from livers corre-
sponding to rats in the study. Pooling was conducted at the RNA level, where equal amounts of RNA were
pooled from four replicate rats at each dose–time point. Sites 2, 3, 6, and 8 received samples from each
dose–time combination derived from studies run at both sites A and B, whereas sites 4, 5, and 7 received
samples corresponding to all dose–time combinations derived from site B only.most 3´ sequence in the cluster. The
oligonucleotide probes are 25mers, and 16
probe pairs per sequence are used. The
detection sensitivity is 1:100,000, measured
by the detection in a comparative analysis
between a complex RNA containing spiked
control transcripts and a complex RNA
with no spikes [Anonymous. GeneChip Rat
Genome U34 Set data sheet (Affymetrix
2002)]; detection is quantitative over more
than three orders of magnitude (Lockhart
et al. 1996). Each site is identiﬁed as a user
in the HESI consortium in Table 1. Sites 2,
3, 6, and 8 analyzed RNA samples from
both in vivo studies performed at sites A and
B, whereas the remaining sites analyzed only
the RNA samples from site B. Each RNA
set was analyzed using nine Affymetrix
chips, one for each of the three dose levels
and three time points, with the exception of
site 3, where all nine chips were used in
three technical replicates of the RNA sam-
ples from three doses from the third time
point from the in vivo study performed at
site A only. Data for perfect match probe
intensities from .CEL files were used for
analysis. In this article we focus on the point
that site effects exist but can be statistically
accounted for and adjusted. It would be
interesting to investigate whether using dif-
ferent normalization methods or outcome
variables (such as perfect match and mis-
match) results in different site-effect magni-
tude, but this was not a major goal of this
article. Data used in this report may be fur-
ther analyzed by interested scientists and
can be accessed via the Internet (http://dir.
niehs.nih.gov/microarray/ilsi-datasets/
home.htm or the European Bioinformatics
Institute ArrayExpress database at http://
www.ebi.ac.uk/arrayexpress/).
A log2 transformation was applied to all
data before any analysis process. As a first
attempt to inspect data consistency across
sites, box plots of all chips were generated
in Figure 2A for comparison of the distrib-
ution of each chip. As shown in Figure 2A,
the within-site chip-to-chip variation is
higher in sites 3 and 5. In addition, the
range of data varies significantly from site
to site. To further inspect the correlations
among chips, a subgroup of 10 chips corre-
sponding to control animals (the ﬁrst level
of dose factor, i.e., dosed with vehicle alone
or the 0 mg/kg dose) at day 1 (the first
level of time factor) was chosen to compute
the interchip correlation coefficients.
Figure 3A shows the scatterplots of the log2
perfect-match probe intensities among the
10 chips. The red ellipse curve within each
plot indicates the 95% density curve based
on bivariate normal distribution (i.e., 95%
of data is inside the ellipse). The pairwise
correlation coefﬁcients ranged from 0.92 to
0.98 except for those from site 3 (B01_3)
or site 5 (B01_5), which ranged from 0.82
to 0.90. 
Another method used to inspect the
consistency of these chips is examination of
Oligo B2 (Affymetrix 2002). The Oligo B2
contains the Poly-A Controls (dap, lys, phe,
thr, and trp) and the Hybridization
Controls (bioB, bioC, bioD, and cre) as part
of the GeneChip Eukaryotic Hybridization
Control Kit. Details on Oligo B2 can be
found in the reference provided. Briefly,
Oligo B2 serves as spike-in controls. The
Poly-A Controls can be spiked into a
complex RNA sample and carried through
the sample preparation process. The
Hybridization Controls are prepared in
staggered concentrations (1.5, 5, 25, and
100 pM for bioB, bioC, bioD, and cre,
respectively) independent of RNA sample
preparation and are spiked into the
hybridization cocktail. Although in the
Affymetrix reference it states that the varia-
tion in B2 hybridization intensities across
the array is normal and does not indicate a
variation in hybridization efficiency, we
have often observed that these controls are
expressed consistently across chips (unpub-
lished data). Figure 3B presents the
scatterplots of Oligo B2 controls among the
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Table 1. User identiﬁers of seven sites in HESI consortium.
User ID Site  RNA sample applied
2 Novartis AG A, B
3 Roche Molecular Biochemicals A, B
4 Wyeth Research B
5 AstraZeneca Pharmaceuticals, Inc. B
6 Schering-Plough Research Institute A, B
7 Boehringer-Ingelheim Pharmaceuticals, Inc. B
8P ﬁzer Inc A, B
Figure 2. (A) Box plots of log2 perfect-match probe intensities. Each site indicated by color is listed from
left (site 2) to right (site 8). Within site, the order of chips is sorted by RNA sample, dose, and time point,
sequentially. Marks on x-axis indicate the associated site and RNA sample. (B) Box plots of log2 perfect-
match probe intensities after interquartile normalization. 
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A10 chips in Figure 3A. A small percentage
of the Hybridization Controls on the chips
were saturated. The linearity (correlation)
between chips was higher when there were
no saturated intensities. The Poly-A
Controls have a better consistency than
Hybridization Controls. Because the Poly-A
Controls are carried in RNA samples
through the preparation process, they are
better candidates to indicate the consistency
of data. The correlation coefﬁcients among
the Poly-A Controls were calculated and
listed in Table 2. These correlation coeffi-
cients revealed that sites 3, 4, and 5 have
less consistency with other chips. However,
the inspection here was based on assuming
all experiments followed the same protocol.
For a global view of the correlations
among all chips, a matrix with each entry as
one minus the correlation coefﬁcient of the
corresponding pair of chips was calculated
and used as the distance matrix for multidi-
mensional scaling (MDS) analysis with the
MDS procedure (SAS Institute 1999). The
results are presented in Figure 4. This two-
dimensional representation gives the relative
location of each chip based on the distance
matrix of a multidimensional space (a
dimension of 99 in this case). The plotted
points are their relative location on a two-
dimensional map. The closer two points are
to each other, the more similar they are.
The chips from sites 3 and 5 are spotted
apart from the others except for the three
chips from site 3 on the margin. 
For a quick summary of the consistency,
the 99 chips were separated into 18 cate-
gories based on the unique site of in vivo
studies, dose, and time combination, and
the average within-category correlation coef-
ficients were calculated. The results are
shown in Figure 5. The average correlation
coefﬁcients in all categories were higher than
0.9. Categories that did not involve sites 3,
4, and 5 (A01, A02, A11, A12, A21, and
A22 in Figure 5) because the site A samples
were not analyzed at those sites, had correla-
tion coefﬁcients higher than 0.95. 
Three major characteristics were
revealed on inspection of the aforemen-
tioned probe data, namely, different
within-site chip-to-chip variation, different
site-to-site variation, and high within-treat-
ment-group correlation across sites. The
ﬁrst characteristic can be handled with the
mixed-model approach and will be dis-
cussed later in this article. The site-to-site
variation can be reduced by normalization.
As seen on examination of the box plots in
Figure 2A, there are two factors that need
normalization: the range of data and the
within-chip variance (size of the box). An
interquartile normalization with the
median as the location parameter and
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Figure 3. (A) Scatterplots of log2 perfect-match probe intensity among the 10 chips with controlling dose
level on day 1. The first letter and the last digital of the marks in the diagonal indicate the RNA sample
used and the site identiﬁer, respectively. (B) Scatterplots of spiked-in probes among the 10 chips. Poly-A
and Hybridization Controls are indicated by blue and green, respectively.
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was applied. Figure 2B presents the box
plots after normalization. The observation
of a high within-treatment-group correla-
tion across sites provides an incentive to
pool data across sites for more powerful
statistical inferences. 
Mixed-Model Analysis
The mixed-model approach provides ﬂexible
model speciﬁcation for the ANOVA type of
analysis with the ability to accommodate
different correlation structures in the data.
Chu et al. (2002) have more details for
applying the mixed model on GeneChip
probe data. The mixed model for the MP
data applied here is as follows:
Yijklp = Ri + Dj + Tk + Sl + RDij + RTik
+ RSil + DTjk + DSjl + TSkl + Pp
+ RPip + DPjp + TPkp + SPlp
+ Aijk(l) + εijklp ,
Aijk(l) ~ N(0, _l
2),
εijklp ~ N(0, σ2). [1]
The indices i, j, k, l, and p indicate site of
in vivo study, dose, time point, site, and
probe number, respectively. The index of
the gene was omitted in the model, as the
model will be run on a per-gene basis. The
dependent variable Y is the normalized
perfect match probe intensity. The sym-
bols R, D, T, S, P represent RNA samples,
dose, time, site, and probe main effects,
respectively. The symbols with two letters
are the interactions of the two effects asso-
ciated with the letters. The Aijk(l) is the lth
within-site array random effect and is
assumed to be normally distributed with
mean 0 and variance σl
2. Specifying array
random effect induces a correlation across
all observations (probes) on the same chip
(probe set). The εijklp is a stochastic error
and is assumed to be normally distributed
with mean 0 and variance σ2. The two ran-
dom terms are assumed to be independent.
The interactions involving more than
two effects can be included in Model 1.
However, after ﬁtting those higher interac-
tions in the model for several genes, we
observed that those interactions were not
signiﬁcant; therefore, they are not included
in the model. The error term can be parti-
tioned to associate with each site in a simi-
lar fashion to the array random effect.
Because all the within-treatment-group
correlations were higher than 0.9, parti-
tioning error term becomes a minor issue.
In addition, assuming that the errors are
identically distributed can enhance the
strength of pooling data to more accurately
estimate the associated variance.
A desired outcome of this exercise was to
ﬁnd genes responding to different doses at
different time points by performing statisti-
cal testing on dose, time, and dose-by-time
interaction effects. Whether the signiﬁcant
genes selected are consistent across sites was
also of particular interest to parties involved
in this across-site microarray study. This can
be achieved by testing dose-by-site and
time-by-site interactions. 
For comparison purposes, a subset of
18 chips from site 8 is extracted and ﬁtted
by a similar fashion as in Model 1 but
without all site-involved effects. This
single-site model is listed as follows:
Yijkp = Ri + Dj + Tk + RDij + RTik + DTjk
+ Pp + RPip + DPjp + TPkp + Aijk
+ εijklp ,
Aijk ~ N(0, σa
2),
εijklp ~ N(0, σ2). [2]
The signiﬁcances of testing some effects
in this case were compared with the results
from Model 1. For ﬁtting Models 1 and 2,
standard maximum likelihood approaches
are usually best and can be accessed through
software like the MIXED procedure (SAS
Institute 1999). 
Results
The statistical testing results of the 10 ﬁxed
effects that did not involve probe in
Model 1 are presented in Figure 6A. Two
plots, a histogram and a box, are drawn on
negative log10 p-values for each effect among
all genes. Table 3 presents the number of
significant genes selected with controlling
false-positive rate by Bonferroni’s approach
and controlling three different false discov-
ery rates (FDR). The cutoff of the negative
log10 p-value for 0.05 family-wide false-posi-
tive rate with Bonferroni’s adjustment in
this case is 6.245, which is indicated as the
red horizontal line on each plot in
Figure 6A. As expected, the site effect is
highly significant for most of the genes
(95.7%). The percentage of signiﬁcant genes
for both dose and time-by-site interactions
were 0.11 and 0.19, respectively. This
implies that only 27 of 8,799 genes showed
a differential response to dose or time across
sites. Therefore, the genes selected as differ-
entially responsive to dose or time from the
pooled data sets is consistent across sites
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Table 2. Correlation coefﬁcients of Poly-A Controls of the 10 chips selected.
A01_2 B01_2 B01_3 B01_4 B01_5 A01_6 B01_6 B01_7 A01_8 B01_8
A01_2 1.00 0.90 0.71 0.66 0.78 0.84 0.83 0.80 0.89 0.90
B01_2 1.00 0.78 0.71 0.80 0.94 0.95 0.86 0.95 0.96
B01_3 1.00 0.59 0.69 0.82 0.77 0.73 0.78 0.78
B01_4 1.00 0.62 0.73 0.74 0.80 0.72 0.68
B01_5 1.00 0.79 0.77 0.72 0.80 0.78
A01_6 1.00 0.96 0.87 0.94 0.92
B01_6 1.00 0.89 0.94 0.94
B01_7 1.00 0.87 0.86
A01_8 1.00 0.95
B01_8 1.00
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Figure 4. Two-dimensional representation of
multidimensional scaling analysis on the 99 chips.
Color indices are the same as in Figure 2.
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Figure 5. Average correlation within each combination of RNA sample, dose, and time point. The first,
second, and third digits in the mark of x-axis indicate RNA sample, dose, and time-point-levels.except for a very few. However, there were
seven genes showing a very highly signiﬁcant
dose effect with a negative logarithm p-value
larger than 10 that also showed a signiﬁcant
dose-by-site interaction. An explanation for
this is that the extremely significant main
effect often causes significant interactions
with other effects. The results of testing the
fixed effects of Model 2 with data from
site 8 only are presented in Figure 6B. All
the negative logarithm p-values are < 6 in
this case. This implies that there were no
genes showing any significant effect with
Bonferroni’s criterion when data from site 8
only were used. 
Compared with Bonferroni’s approach,
which conservatively guarantees that the
probability of only one (or more) false pos-
itives is less than 0.05 across all of the tests,
FDR allows a certain proportion (the cut-
off rate) of signiﬁcant genes to be false dis-
coveries. More significant genes were
selected with FDR approaches. However,
the proportion of genes with significant
dose or time-by-site effects was still consid-
erably low—1.3 and 2.2% in the case of
setting 0.005 (1 in 200) as cutoff. 
The results in Table 3 reveal that
site-to-site effects, although signiﬁcant in a
large number of genes, appear to be only
additive, as Model 1 ﬁt the data well, with a
median r2 equal to 0.97, and only a few
genes showed significant site-by-treatment
interaction. Therefore, this can be adjusted
for in the statistical calculations in a way that
does not bias conclusions regarding treat-
ment differences. In other words, each site
ends up relaying a similar story regarding sig-
niﬁcantly differentially expressed genes.
Figure 7 presents the histograms and
box plots of the standard deviations of the
random components that are seven within-
site array random factors, Aijk(l), and the
stochastic errors, εijklp, in Model 1. These
plots provide global comparisons among
the site-specific array variations. The data
from sites 6 and 7 show less array variation,
whereas the data from sites 3 and 5 show
larger array variation. The median standard
deviations of sites 2–8 and stochastic errors
are 0.029, 0.089, 0.037, 0.087, 0.018,
0.018, 0.024, and 0.096, respectively.
Judging from comparison of these medi-
ans, the array variations from sites 3 and 5
are about 23-fold (0.0892/0.0182) larger
than the variations from sites 6 and 7.
Figure 8 presents the comparison of
significance of dose and time effects from
Models 1 and 2. The red lines on plots are
regression-ﬁtted lines with slopes 0.14 and
0.16 on Figure 8A (comparing signiﬁcance
of dose effect) and Figure 8B (comparing
significance of time effect), respectively.
Pooling data across sites increases statistical
inference power signiﬁcantly. Judging from
the inverse of slopes, the negative log p-values
increase 7.14- and 6.25-fold for dose and
time effects, respectively, when pooling data
across seven sites, with the number of chips
applied increasing from 18 to 99. 
Discussion
Combining data across sites typically
provides more powerful statistical inference.
However, consistency of data sets is an
essential issue for analyzing pooled data sets
across sites. A robust normalization method
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Table 3. Number of signiﬁcant genes selected by the 10 effects without probe involved.
Number of signiﬁcant genesa
Effect Bonferroni FDR (0.005)
b FDR (0.01)
b FDR (0.05)
b
R 466 (5.3) 1,620 (18.4) 1,851 (21.0) 2,605 (29.6)
D 787 (8.9) 1,900 (21.6) 2,159 (24.5) 3,067 (34.9)
T 173 (2.0) 735 (8.4) 890 (10.1) 1,539 (17.5)
S 8,422 (95.7) 8,746 (99.4) 8,762 (99.6) 8,792 (99.9)
RD 33 (0.38) 274 (3.1) 352 (4.0) 714 (8.1)
RT 361 (4.1) 972 (11.0) 1,144 (13.0) 1,738 (19.8)
RS 1,921 (21.8) 5,031 (57.2) 5,443 (61.9) 6,509 (73.3)
DT 507 (5.8) 1,504 (17.1) 1,735 (19.7) 2,690 (30.6)
DS 10 (0.11) 112 (1.3) 149 (1.7) 421 (4.8)
TS 17 (0.19) 190 (2.2) 308 (3.5) 970 (11.0)
Abbreviations: D, dose; DS, dose–site; DT, dose–time; R, RNA sample; RD, RNA sample - dose; RS, RNA sample - site; RT,
RNA sample - time; S, site; T,time; TS, time–site. 
aResults of false discovery rate (FDR), with 0.005, 0.01, and 0.05 as the cutoffs. bThe percentage of signiﬁcant genes of
each effect is listed inside parentheses after the counts of signiﬁcant genes.
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B Figure 6. (A) Histograms and box
plots of negative log10 p-values of
the fixed effects in Model 1.
Bonferroni’s cutoff is indicated by
red horizontal line. Red and blue
points in box plots indicate the
genes having significant dose-by-
site and time-by-site interactions,
respectively. (B) Histograms and box
plots of negative log10 p-values of
the fixed effects when data from
site 8 only were applied. is desirable to make data sets across sites
more comparable. The interquartile range
normalization is suitable for data with high
correlation but inconsistent data range
across chips. This normalization was used
on the data applied here to achieve consis-
tent ranges across the majority of the data
and to preserve the phenomena of
signiﬁcant site variation. 
An alternative means for normalizing
data across sites is to use a universal refer-
ence sample. The universal reference is typi-
cally a type of mRNA pool from all the mice
in the experiment and is distributed to each
site of the consortium to serve as baseline for
normalization. Data can be normalized
within each site to the universal reference
array, using linear or nonlinear methods.
The advantage of a universal reference is
that it serves as a bridge to bring the data
from all chips across sites to be comparable;
however, extra costs are involved in prepara-
tion, distribution, and maintenance of the
pooled reference as well as the expense of
running more arrays. In addition, data from
the reference are subject to nonconstant
within-site sources of variability and do not
provide a gold standard for comparison.
This concern will be more serious for sites
with high within-site array-to-array variation
Rather than using the data from the
whole array for normalization, another alter-
native is to use a portion of the data consid-
ered to be invariant across arrays to generate
a scoring function for normalization (Li and
Wong 2001; Schadt et al. 2001). Those
probes in Affymetrix provided as Oligo B2
can be considered invariant with known
concentrations. Again, the quality of those
controls is key to the success of this
approach, and we are currently investigating
ways of implementing this approach.
The mixed model provides a flexible
method to adjust site effects and to use dif-
ferent array variations between sites.
Signiﬁcant site effects were revealed by this
analysis as expected; however, only a few
genes showed signiﬁcant interaction effects
between sites and treatments, dose, or time.
In other words, each site tends to tell the
same story regarding the list of signiﬁcantly
differentially expressed genes. This is a pri-
marily positive result from this study and
lends hope to the prospect of gaining power
by combining study results. Similar studies
are needed to extend this type of analysis to
investigation of cross-platform data sets.
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Figure 8. Scatterplots of negative log10 p-values of testing dose (A) and time (B) effects from Model 1 with
data from seven sites and Model 2 with data from site 8 only. The red lines are regression-ﬁtted lines with
slopes 0.14 and 0.16 on A and B plots, respectively.
Figure 7. Histograms and box plots of the standard deviations of the random components, seven within-
site array random factors and the stochastic errors, in Model 1. 
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